An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European Journal of Cancer

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2011.06.054PMID 21803569
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new patient‐focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options

  2011cited by this paper
• [Recommendations Onco-Urology 2010: Kidney cancer].

  2010cited by this paper
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.

  2010cited by this paper
• Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

  2010cited by this paper
• EAU guidelines on renal cell carcinoma: the 2010 update.

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

  2010cited by this paper
• Phase 3 trial of everolimus for metastatic renal cell carcinoma

  2010cited by this paper
• Recommandations en Onco-Urologie 2010 : Cancer du rein

  2010cited by this paper
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• EORTC-GU group expert opinion on metastatic renal cell cancer.

  2009cited by this paper
• Targeted therapies: Sunitinib in RCC—expanded access equals expanded benefit?

  2009cited by this paper
• Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

  2009cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

  2009cited by this paper
• Metastatic renal cell carcinoma: many treatment options, one patient.

  2009cited by this paper
• Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• NCCN Task Force Report: mTOR inhibition in solid tumors.

  2008cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Renal-cell carcinoma--molecular pathways and therapies.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

  2004cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper

• Effect of Interval Between Neoadjuvant Chemotherapy and Surgery on Oncological Outcomes in Poor Responders With Locally Advanced Breast Cancer

  2024cites this paper
• Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma

  2021cites this paper
• Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma

  2020cites this paper
• Cytoreductive Nephrectomy Combined With Sequential Targeted Therapy For Treating Multiple Bilateral Metastatic Renal Cell Carcinoma: A Case Report

  2020cites this paper
• Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment

  2020cites this paper
• Real-World Outcome of 173 Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC) Cases: The Experience of the Center Group for Genitourinary Tumors

  2019cites this paper
• Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM

  2019cites this paper
• Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma

  2019influential citation
• Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma

  2019influential citation
• Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)

  2019cites this paper
• Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo

  2019cites this paper
• Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country: Real-life single institutional experience

  2018cites this paper
• A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study

  2018cites this paper
• Pharmacotherapy for treating metastatic clear cell renal cell carcinoma

  2017cites this paper
• The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges

  2017cites this paper
• Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results

  2017cites this paper
• Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib

  2017cites this paper
• The effect of hydroxy safflower yellow A on coronary heart disease through Bcl-2/Bax and PPAR-γ.

  2017cites this paper
• A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France

  2017cites this paper
• Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.

  2017cites this paper
• Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma

  2017cites this paper
• Renal Cell Carcinoma

  2017cites this paper
• Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus

  2017cites this paper
• Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action

  2017cites this paper
• Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study

  2016cites this paper
• The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma

  2016cites this paper
• Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy.

  2016cites this paper
• Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

  2016cites this paper
• Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

  2016cites this paper
• Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).

  2016cites this paper
• Complete response in metastatic renal cell carcinoma after radiotherapy and everolimus: a clinical case and review of the literature

  2016cites this paper
• Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line

  2016cites this paper
• Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

  2016cites this paper
• Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.

  2016cites this paper
• Clinical management of metastatic kidney cancer: the role of new molecular drugs.

  2016cites this paper
• Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

  2016cites this paper
• Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy

  2016cites this paper
• RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.

  2015cites this paper
• Current and future strategies in nonclear-cell metastatic renal cell carcinoma

  2015cites this paper
• [PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB].

  2015cites this paper
• Non-clear cell renal cell carcinoma, part 2: therapy.

  2015cites this paper
• Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.

  2015cites this paper
• Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies

  2015cites this paper
• The Role of Targeted Therapy in Special Populations

  2015cites this paper
• Future perspectives for mTOR inhibitors in renal cell cancer treatment.

  2015cites this paper
• Everolimus treatment in advanced solid tumors: a personal view

  2015cites this paper
• Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?

  2015cites this paper
• Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

  2015cites this paper
• The Role of Everolimus in Renal Cell Carcinoma

  2015cites this paper
• Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma

  2015cites this paper
• Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.

  2015influential citation
• Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma.

  2015cites this paper
• Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study

  2015cites this paper
• REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis.

  2015cites this paper
• Treatment-related fatigue with everolimus and temsirolimus in patients with cancer—a meta-analysis of clinical trials

  2015cites this paper
• We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.

  2014cites this paper
• Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer.

  2014cites this paper
• Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres

  2014cites this paper
• Making sense of dietary calcium and urinary stone disease

  2014cites this paper
• Fatal case of cryptogenic organizing pneumonia associated with Everolimus

  2014cites this paper
• A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.

  2014cites this paper
• The ORCHIDEE Study: Gathering New Evidence on the use of Everolimus in Clinical Practice

  2014cites this paper
• Drugs that act on the immune system: Immunosuppressive and immunostimulatory drugs

  2014cites this paper
• Drugs that act on the immune system

  2014cites this paper
• Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.

  2014cites this paper
• Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms

  2014cites this paper
• METASTATICRENAL CANCER:PROGNOSTIC ANDPREDICTIVEBIOMARKERS REVIEW

  2014cites this paper
• Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists.

  2014cites this paper
• Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor

  2014cites this paper
• Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.

  2013cites this paper
• Phase II study of everolimus in metastatic urothelial cancer

  2013cites this paper
• The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma

  2013cites this paper
• Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

  2013cites this paper
• Individualising treatment choices in a crowded treatment algorithm

  2013cites this paper
• A CASE OF MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA FAILING TO RESPOND TO INTERFERON-α (IFN-α) AND SUNITINIB BUT MARKEDLY RESPONDING TO EVEROLIMUS

  2013cites this paper
• [Case of multiple lung metastases of renal cell carcinoma failing to respond to Interferon-alpha (IFN-alpha) and sunitinib but markedly responding to everolimus].

  2013cites this paper
• Advanced kidney cancer: treating the elderly

  2013cites this paper
• mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.

  2013cites this paper
• Proposal of “cyclic therapy”, a novel treatment strategy with targeted agents for advanced renal cell carcinoma

  2013cites this paper
• Chemotherapy in metastatic renal cell carcinoma today? A systematic review

  2013cites this paper
• Targeting receptor tyrosine kinases in solid tumors.

  2013cites this paper
• Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial

  2013cites this paper
• A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.

  2013cites this paper
• Clinical biomarkers of response in advanced renal cell carcinoma.

  2013cites this paper
• Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.

  2012cites this paper
• Sitzungsbericht der AG Uropathologie

  2012cites this paper
• Variant Renal Cell Carcinoma Histologies: Therapeutic Considerations

  2012cites this paper
• Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?

  2012cites this paper
• Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.

  2012cites this paper
• Sitzungsbericht der AG Uropathologie

  2010cites this paper